New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
17:55 EDTMNK, QCORQuestcor's Acthar risks not included in Mallinckrodt's merger proxy, NYT says
Risks regarding the increase of adverse events related to Questcor's (QCOR) drug Acthar need to be considered by Mallinckrodt's (MNK) shareholders. Those risks were not included in last month's merger proxy, reports the New York Times. Reference Link
News For MNK;QCOR From The Last 14 Days
Check below for free stories on MNK;QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:30 EDTMNKCRT Capital to hold a conference
2nd Annual Investor Conference to be held in Greenwich, CT on September 16.
September 4, 2014
09:02 EDTMNKMallinckrodt announces MNK-155 Phase 3 efficacy trial met primary endpoint
Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014 on September 2-6. In addition to the Phase 3 study, Mallinckrodt will present data at PAINWeek from several other MNK-155 trials, including the pharmacokinetics, safety and subjective effects of abuse-related characteristics.
September 3, 2014
09:07 EDTMNKMallinckrodt reported MNK-155 HAL study data
Subscribe for More Information
07:53 EDTMNKMallinckrodt management to meet with Deutsche Bank
Meeting to be held in New York on September 3 hosted by Deutsche Bank.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use